Skip to content
Review

The clinical utility of blood-based biomarkers of Alzheimer's disease: Triumphs and pitfalls.

2026 · International review of neurobiology · Vol 191, pp. 403-446 · 0 citations
Medicine

TL;DR

This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.

View source

Similar papers

Review 2026

Blood-based biomarkers in Alzheimer's and Parkinson's disease: From molecular pathology to therapeutic potential.

This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.

Priya, Radhika Mittal, Jyotirmoy Banerjee et al. · 0 citations
Review 2026

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.

Greata Rubavathi Eliazer, Mahesh Kandasamy · 0 citations
Review Sep 2026

Blood-based biomarkers in the anti-amyloid era of Alzheimer's disease: clinical utility, implementation challenges, and future directions.

BACKGROUND Implementation of disease-modifying anti-amyloid therapies for Alzheimer's disease remains constrained by the cost and procedural burden of positron emission tomography and cerebrospinal fluid testing. This review evaluates blood-based biomarkers in therapeutic pathways. METHODS PubMed/MEDLINE and Embase w...

Bo-Lin Ho, Yuan-Han Yang · 0 citations
Review 2026

The emerging landscape of circulatory biomarkers in Alzheimer's disease.

This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.

Sakshi Kumari, Amaan Rais, Mohd Suhail Ashar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.